Securities code: 600645 securities abbreviation: Vcanbio Cell & Gene Engineering Corp.Ltd(600645) Announcement No.: 2022-007 Vcanbio Cell & Gene Engineering Corp.Ltd(600645)
Announcement on the resolutions of the 14th extraordinary meeting of the 10th board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Vcanbio Cell & Gene Engineering Corp.Ltd(600645) (hereinafter referred to as “the company”) the 14th interim board meeting of the 10th session was held by means of communication voting on February 18, 2022. The meeting notice and meeting materials have been sent to all directors by email on February 11, 2022. There are 8 directors who should attend the meeting and 8 directors who actually attend the meeting. The meeting complies with the provisions of the company law and the articles of association, and the voting is valid. After careful deliberation by the directors present at the meeting, the following resolutions were adopted:
1. The proposal on the signing of real estate leasing contract and related party transactions between the holding subsidiary and Shanghai Yanli Biotechnology Co., Ltd. was deliberated and adopted by 7 votes in favor, 0 against and 0 abstention;
For details, see the announcement of the company on the signing of real estate leasing contract and related party transaction between the holding subsidiary and Shanghai Yanli Biotechnology Co., Ltd. on the same day.
Ms. Wu Shan, a related director, abstained from voting.
2. The proposal on adjusting the remuneration of senior managers was deliberated and adopted by 8 votes in favor, 0 against and 0 abstention.
In order to improve the incentive and restraint mechanism of managers, effectively mobilize the enthusiasm and creativity of senior executives, and take into account the salary level of senior executives of Companies in the same industry, the company plans to adjust the salary of senior executives from 2022, with an average increase of 30% for all senior executives, which was deliberated and approved by the salary and assessment committee of the board of directors at its first meeting in 2022.
It is hereby announced.
February 19, 2002
